Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in theme_biblio_custom() (line 367 of /home/phcogcommn/

Aleurites moluccanus (l.) Willd. Extracts Inhibit the Growth of Bacterial Triggers of Selected Autoimmune Inflammatory Diseases


Pharmacognosy Communications,,2017,7,2,83-90.
Published:May 2017
Type:Original Article

Aleurites moluccanus (l.) Willd. Extracts Inhibit the Growth of Bacterial Triggers of Selected Autoimmune Inflammatory Diseases

Lindiwe Nomathemba Mpala1, Getmore Rumbudzai Chikowe1, Ian Edwin Cock1,2*

1School of Natural Sciences, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, Australia.

2Environmental Futures Research Institute, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, Australia.


Introduction: Aleurites moluccanus (L.) Willd. is a large tree with a wide global distribution. All parts of the tree have been used medicinally and the nut is consumed in a variety of cuisines. Despite this, A. moluccanus nut extracts have not been rigorously examined growth inhibitory properties against many bacteria, including the bacterial triggers of autoimmune inflammatory diseases. Methods: The antimicrobial activity of A. moluccanus nut solvent extractions was investigated by disc diffusion and growth time course assays against a panel of bacterial triggers of autoimmune diseases. The growth inhibitory activity was further quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Methanolic and aqueous A. moluccanus nut solvent extracts were potent inhibitors of all of the bacterial triggers of autoimmune diseases screened in this study. The methanolic extract displayed the most potent bacterial growth inhibitory activity. It was particularly potent against the bacterial triggers of rheumatoid arthritis (MICs of 438 and 215 μg/mL against reference and clinical Proteus mirabilis strains; MIC of 187 μg/mL against Proteus vulgaris). The methanolic extract was also a good inhibitor of K. pneumoniae and S. pyogenes growth with MICs < 1000 μg/mL. The aqueous and ethyl acetate extracts were also potent bacterial growth inhibitors, albeit with slightly higher MIC values. The antibacterial activity of the methanolic and aqueous A. moluccanus nut extracts were further investigated by growth time course assays which showed significant growth inhibition in cultures of P. mirabilis, K. pneumpniae and S. pyogenes within 1 h of exposure. All extracts were determined to be nontoxic in the Artemia franciscana nauplii bioassay, indicating their safety for prophylactic use in preventing these autoimmune inflammatory diseases. Conclusions: The lack of toxicity of the A. moluccanus nut extracts and their growth inhibitory bioactivity against the bacterial triggers of rheumatoid arthritis, ankylosing spondylitis and rheumatic heart disease indicate their potential in the development of new therapies targeting the onset of these diseases. 

Founded:  In 2004, as the PHCOG.NET – a non-profit private organization dedicated to Natural Products Research leading to develop promising drugs. Our main mission is to make information on herbal drug research readily available in different formats to suit the individual needs.

Pharmacognosy Communications [Phcog Commn.] is a new quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the  publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.

The journal aims to cater the latest outstanding developments in the field of pharmacognosy and natural products and drug design covering but not limited to the following topics:

  • Pharmacognosy and pharmacognistic investigations
  • Research based ethnopharmacological evaluations
  • Biological evaluation of crude extracts, essential oils and pure isolates
  • Natural product discovery and evaluation
  • Mechanistic studies
  • Method and technique development and evaluation
  • Isolation, identification and structural elucidation of natural products
  • Synthesis and transformation studies

Distinctions:  The most widely read, cited, and known Pharmacognosy Communications and website is well browsed with all the articles published. More than 20,000 readers in nearly every country in the world each month

Aim and Scope | Editorial Board | Indexed & Abstracted | Instruction to Authors | Manuscript Submission & Charges

Subjects Covered : Natural Products, Pharmacognosy, Phytochemistry, Marine Pharmacognosy and Zoo Pharmacognosy
ISSN :2249-0159 (Print) ; 2249-0167 (Online) Frequency : Quarterly Rapid at a time publication (4 issues/year)

Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online  publication is 45 days.
Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.